ArticleCancer cell international2025
Elevated expression and secretion of TGF-α contribute to Temozolomide resistance in human glioblastoma cells.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- miR-152-3p Overcomes Temozolomide Resistance in Glioblastoma by Targeting TGF-α and Enhancing Apoptosis.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor often treated with Temozolomide (TMZ). Research reveals that secretory substances and receptor-activated signaling may contribute to TMZ resistance in GBM cells. RNA-Seq and bioinformatics analyses reveal that TMZ treatment downregulates most genes, particularly those involved in cell structure and metabolism, while activating genes linked to secretory substances like cytokines, chemokines, and growth factors. Antibody array analysis identified a significant increase in TGF-α secretion after TMZ treatment, which also triggered its associated pathways. Moreover, the remarkable secretion of TGF-α also triggered the activation of its associated pathways. Notably, a marked increase in TGF-α expression was observed in TMZ-resistant cells. TGF-α knockdown restored TMZ sensitivity in a mouse xenograft model. Tissue analysis revealed significantly higher TGF-α levels in GBM, suggesting its potential as a drug resistance biomarker and target for new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.